{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:13:57Z","timestamp":1792502037070,"version":"4.5.0"},"reference-count":112,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:00:00Z","timestamp":1764374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K23DA052682"],"award-info":[{"award-number":["K23DA052682"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R21DA057240"],"award-info":[{"award-number":["R21DA057240"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R25MH071584"],"award-info":[{"award-number":["R25MH071584"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Substance Use &amp; Addiction Journal"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Opioid-related deaths remain a major cause of preventable mortality, but access to medications for opioid use disorder (MOUD) such as methadone and buprenorphine remains restricted globally. This review compares national MOUD policies across 8 countries (the United States, Canada, the United Kingdom, Russia, France, Iran, Australia, and Portugal) to examine how regulation may affect treatment coverage, mortality, and system responsiveness. Secondary aims include identifying barriers to MOUD access and illustrating potential lives saved and economic gains from expanded U.S. coverage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A targeted narrative review of peer-reviewed and policy literature characterized methadone and buprenorphine regulations, prescriber eligibility, dispensing models, and coverage across countries, with opioid-related mortality data drawn from the Global Burden of Disease Study 2021. A U.S. modeling analysis estimated overdose deaths averted and economic savings at increasing levels of MOUD coverage using national prevalence data, meta-analytic mortality reductions from treatment, and Centers for Disease Control and Prevention economic valuations adjusted for treatment costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Regulatory bottlenecks including daily supervised dosing, restricted community prescribing, and stigmatizing drug scheduling limit MOUD access. International models demonstrate feasible alternatives: in the U.K. and Australia, community pharmacy dispensing supports reach without compromising safety; in France, liberal buprenorphine prescribing through primary care facilitated rapid national scale-up; in Portugal and Iran, decriminalization and expansion of flexible, low-threshold public health-integrated models coincided with reductions in overdose deaths. In contrast, Russia\u2019s prohibition underscores the harms of abstinence-only policies. Increasing U.S. MOUD coverage to 25% could prevent about 3500 overdose deaths annually, and universal coverage could avert over 41\u2009000, yielding $38 to $444\u2009billion in net economic savings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>International evidence suggests that regulatory reform and integration of MOUD into mainstream healthcare can expand access and reduce mortality. Aligning policies with these lessons, by decentralizing methadone delivery, modernizing buprenorphine scheduling, and embedding MOUD within public health systems, represents both a public health and economic imperative.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/29767342251392342","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T15:11:23Z","timestamp":1764429083000},"page":"595-610","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Expanding Access to Buprenorphine and Methadone: Global Perspectives and Policy Recommendations"],"prefix":"10.1177","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9622-3361","authenticated-orcid":false,"given":"Julio C.","family":"Nunes","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Yale University, New Haven, CT, USA"},{"name":"Department of Psychiatry, West Haven Veteran Affairs, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel P. A.","family":"Costa","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Yale University, New Haven, CT, USA"},{"name":"Department of Psychiatry, West Haven Veteran Affairs, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao P.","family":"De Aquino","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Yale University, New Haven, CT, USA"},{"name":"Department of Psychiatry, West Haven Veteran Affairs, CT, USA"},{"name":"Clinical Neuroscience Research Unit, Yale University, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryon","family":"Adinoff","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Colorado Anschutz Medical Campus, Aurora, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,11,29]]},"reference":[{"key":"e_1_3_2_2_2","unstructured":"Center for Disease Control. Provisional drug overdose death counts. 2025. Accessed August 28 2025. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm"},{"key":"e_1_3_2_3_2","unstructured":"World Health Organization. Opioid overdose. Accessed August 29 2025. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/opioid-overdose"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108350"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-018-0097-6"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-018-0094-5"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104487"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-020-06257-4"},{"key":"e_1_3_2_9_2","unstructured":"Substance Abuse and Mental Health Services Administration. Federal guidelines for opioid treatment programs. Accessed September 01 2025. https:\/\/store.samhsa.gov\/product\/federal-guidelines-opioid-treatment-programs\/pep15-fedguideotp"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/add.15087"},{"key":"e_1_3_2_11_2","unstructured":"Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2021. Institute for Health Metrics and Evaluation (IHME). Accessed August 28 2025. https:\/\/vizhub.healthdata.org\/gbd-results\/"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2023.100557"},{"key":"e_1_3_2_13_2","unstructured":"Substance Abuse and Mental Health Services Administration. 2023 National Survey on Drug Use and Health (NSDUH). Accessed August 27 2025. https:\/\/www.samhsa.gov\/data\/release\/2023-national-survey-drug-use-and-health-nsduh-releases"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1550"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7015a1"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.12562"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1080\/00952990.2021.1979991"},{"key":"e_1_3_2_18_2","unstructured":"Substance Abuse and Mental Health Services Administration. Medications for the treatment of opioid use disorder: final rule. Fed Regist. 2024;89(23):7528-7563. Accessed August 27 2025. https:\/\/www.federalregister.gov\/documents\/2024\/02\/02\/2024-01693\/medications-for-the-treatment-of-opioid-use-disorder"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108276"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104381"},{"key":"e_1_3_2_21_2","unstructured":"Center for Disease Control. U.S. Overdose deaths decrease in 2023 first time since 2018. Accessed August 28 2025. https:\/\/www.cdc.gov\/nchs\/pressroom\/nchs_press_releases\/2024\/20240515.htm"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2023.7570"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.12927\/hcpol.2024.27228"},{"key":"e_1_3_2_24_2","unstructured":"College of Nurses of Ontario. NPs and prescribing controlled substances. Accessed September 30 2024. https:\/\/www.cno.org\/en\/trending-topics\/nps-and-prescribing-controlled-substances\/"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103680"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/add.14947"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.231339"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-019-00790-x"},{"key":"e_1_3_2_29_2","unstructured":"Clinical Guidelines on Drug Misuse and Dependence Update 2017 Independent Expert Working Group. Drug misuse and dependence: UK guidelines on clinical management. Accessed August 28 2025. https:\/\/assets.publishing.service.gov.uk\/media\/5a821e3340f0b62305b92945\/clinical_guidelines_2017.pdf"},{"key":"e_1_3_2_30_2","unstructured":"United Kingdom Department of Health Office for Health Improvement & Disparities. Adult substance misuse treatment statistics 2022 to 2023. Accessed September 01 2025. https:\/\/www.gov.uk\/government\/statistics\/substance-misuse-treatment-for-adults-statistics-2022-to-2023\/adult-substance-misuse-treatment-statistics-2022-to-2023-report"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02351-y"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7517-5-23"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40985-018-0088-5"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30856-X"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-018-0395-y"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(21)00274-5"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30168-1"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(08)61311-2"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0136030"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2015.10.001"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1080\/10826080802289291"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12963-016-0078-0"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-007-0046-2"},{"key":"e_1_3_2_44_2","unstructured":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9 (ANSM). Modification of the maximum prescription duration for methadone AP-HP capsule formulations. Point d\u2019Information. 2023. Accessed August 13 2025. https:\/\/archive.ansm.sante.fr\/S-informer\/Points-d-information-Points-d-information\/Modification-de-la-duree-maximale-de-prescription-des-specialites-Methadone-AP-HP-gelule-Point-d-Information"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/add.14905"},{"issue":"12","key":"e_1_3_2_46_2","first-page":"793","article-title":"Profile of people who inject drugs in Tehran, Iran","volume":"54","author":"Amin-Esmaeili M","year":"2016","unstructured":"Amin-Esmaeili M, Rahimi-Movaghar A, Gholamrezaei M, Razaghi EM. Profile of people who inject drugs in Tehran, Iran. Acta Med Iran. 2016;54(12):793-805.","journal-title":"Acta Med Iran"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108871"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/add.13453"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1080\/09595230701373891"},{"key":"e_1_3_2_50_2","unstructured":"Australian Government Department of Health and Aged Care. National guidelines for medication-assisted treatment of opioid dependence. Accessed September 01 2025. https:\/\/www.health.gov.au\/sites\/default\/files\/national-guidelines-for-medication-assisted-treatment-of-opioid-dependence.pdf"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1111\/dar.13792"},{"key":"e_1_3_2_52_2","unstructured":"Silvestri A. Gateways from crime to health: the Portuguese drug commissions. Accessed September 30 2024. https:\/\/sicad.pt\/BK\/Dissuasao\/Documents\/AS%20report%20GATEWAYS%20FROM%20CRIME%20TO%20HEALTH.pdf"},{"key":"e_1_3_2_53_2","unstructured":"Open Society Foundations. Drug policy in Portugal: the benefits of decriminalizing drug use. Accessed September 30 2024. https:\/\/www.opensocietyfoundations.org\/publications\/drug-policy-portugal-benefits-decriminalizing-drug-use"},{"key":"e_1_3_2_54_2","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. Opioid agonist treatment: the current situation in Europe (European Drug Report 2024). Accessed September 01 2025. https:\/\/www.euda.europa.eu\/publications\/european-drug-report\/2024\/opioid-agonist-treatment_en"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2024.104993"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-020-01199-7"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2020.108146"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102704"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-021-00535-y"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.18452"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2025.104805"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0002168"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1111\/dar.13477"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2017.04.005"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1370\/afm.2920"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1111\/add.70122"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12875-024-02474-6"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2022.108891"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-023-08306-0"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa2212412"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0137708"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7517-9-20"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-023-00386-x"},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1080\/16066359.2024.2420087"},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-021-00263-5"},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.6373"},{"key":"e_1_3_2_77_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.3711"},{"key":"e_1_3_2_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102701"},{"key":"e_1_3_2_79_2","unstructured":"Legal Action Center. Overcoming barriers to buprenorphine in retail pharmacies. 2025. Accessed September 02 2025. https:\/\/www.lac.org\/assets\/files\/Overcoming-Barriers-to-Buprenorphine-in-Retail-Pharmacies.pdf"},{"key":"e_1_3_2_80_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2022.2839"},{"key":"e_1_3_2_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2024.102319"},{"key":"e_1_3_2_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2022.04.019"},{"key":"e_1_3_2_83_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108729"},{"key":"e_1_3_2_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2015.04.009"},{"key":"e_1_3_2_85_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2022.4001"},{"key":"e_1_3_2_86_2","doi-asserted-by":"publisher","DOI":"10.1002\/hec.4255"},{"key":"e_1_3_2_87_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.639826"},{"key":"e_1_3_2_88_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.3474"},{"key":"e_1_3_2_89_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2018.1052"},{"key":"e_1_3_2_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)32259-1"},{"key":"e_1_3_2_91_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2017.3947"},{"key":"e_1_3_2_92_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2020.02261"},{"key":"e_1_3_2_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108449"},{"key":"e_1_3_2_94_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13011-023-00564-9"},{"key":"e_1_3_2_95_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.1271"},{"key":"e_1_3_2_96_2","doi-asserted-by":"publisher","DOI":"10.1177\/11782218221085590"},{"key":"e_1_3_2_97_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2022.108801"},{"key":"e_1_3_2_98_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2022.1776"},{"key":"e_1_3_2_99_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109703"},{"key":"e_1_3_2_100_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0740-5472(03)00040-0"},{"key":"e_1_3_2_101_2","doi-asserted-by":"publisher","DOI":"10.1111\/add.15039"},{"key":"e_1_3_2_102_2","doi-asserted-by":"publisher","DOI":"10.1111\/dar.13382"},{"key":"e_1_3_2_103_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2021.20101548"},{"key":"e_1_3_2_104_2","unstructured":"The Pew Charitable Trusts. UK pharmacies offer sense of normalcy for methadone patients. Fact sheet. 2023. Accessed September 04 2025. https:\/\/www.pew.org\/en\/research-and-analysis\/fact-sheets\/2023\/05\/uk-pharmacies-offer-sense-of-normalcy-for-methadone-patients"},{"issue":"2","key":"e_1_3_2_105_2","first-page":"5","article-title":"Outcomes for patients receiving telemedicine-delivered medication-based treatment for opioid use disorder: a retrospective chart review","volume":"23","author":"Weintraub E","year":"2021","unstructured":"Weintraub E, Greenblatt AD, Chang J, et al. Outcomes for patients receiving telemedicine-delivered medication-based treatment for opioid use disorder: a retrospective chart review. Heroin Addict Relat Clin Probl. 2021;23(2):5-12.","journal-title":"Heroin Addict Relat Clin Probl"},{"key":"e_1_3_2_106_2","doi-asserted-by":"publisher","DOI":"10.1080\/00952990.2025.2525405"},{"key":"e_1_3_2_107_2","unstructured":"Drug Enforcement Administration. Schedules of controlled substances: rescheduling of buprenorphine from Schedule V to Schedule III. Accessed September 03 2025. https:\/\/www.federalregister.gov\/documents\/2002\/10\/07\/02-25293\/schedules-of-controlled-substances-rescheduling-of-buprenorphine-from-schedule-v-to-schedule-iii"},{"key":"e_1_3_2_108_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.51856"},{"key":"e_1_3_2_109_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.29409"},{"key":"e_1_3_2_110_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301479"},{"key":"e_1_3_2_111_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103110"},{"key":"e_1_3_2_112_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2022.108923"},{"key":"e_1_3_2_113_2","doi-asserted-by":"publisher","DOI":"10.1080\/10826084.2023.2177972"}],"container-title":["Substance Use &amp; Addiction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/29767342251392342","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/29767342251392342","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/29767342251392342","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:52:17Z","timestamp":1777600337000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/29767342251392342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,29]]},"references-count":112,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1177\/29767342251392342"],"URL":"https:\/\/doi.org\/10.1177\/29767342251392342","relation":{},"ISSN":["2976-7342","2976-7350"],"issn-type":[{"value":"2976-7342","type":"print"},{"value":"2976-7350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,29]]}}}